Valuation: AstraZeneca PLC

Market Cap 26TCr 23TCr 21TCr 19TCr 36TCr 24,88200Cr 36TCr 2,55700Cr 99TCr 12,65000Cr 97TCr 95TCr 40,70400Cr P/E 2026 *
21.3x
P/E 2027 * 18.6x
Enterprise Value 28TCr 24TCr 23TCr 21TCr 39TCr 26,77100Cr 39TCr 2,75200Cr 1,06200Cr 13,61100Cr 1,04800Cr 1,02500Cr 43,79500Cr EV / Sales 2026 *
4.42x
EV / Sales 2027 * 4.05x
Free-Float
96.63%
Yield 2026 *
1.99%
Yield 2027 * 2.12%
1 day+0.59%
Current year+1.81%
Current year 152.4
Extreme 152.4
166.3
1 year 124.15
Extreme 124.15
166.3
3 years 111
Extreme 111
166.3
5 years 95.25
Extreme 95.25
166.3
10 years 47.72
Extreme 47.715
166.3
Manager TitleAgeSince
Chief Executive Officer 66 01/10/2012
Director of Finance/CFO 52 01/08/2021
Compliance Officer - 01/01/2023
Director TitleAgeSince
Director/Board Member 70 06/04/1999
Director/Board Member 66 01/10/2012
Director/Board Member 65 27/04/2017
Change 5-day change 1-year change 3-year change Capi.($)
+0.59%-.--% - - 26TCr
+0.04%+3.34%+51.12%+101.82% 1,02800Cr
-0.09%+1.66%+55.02%+66.18% 65TCr
-0.02%+2.66%+18.91%+71.47% 47TCr
-1.22%+3.66%+36.44%+38.32% 35TCr
-0.79%+2.73%+19.03%+25.08% 27TCr
+0.58%+6.76%+11.13%+16.52% 26TCr
+1.55%+2.20%+39.81%+46.55% 21TCr
+0.79%+1.84%-28.27%-56.71% 19TCr
-0.52%+4.45%+32.12%+98.51% 19TCr
Average +0.24%+3.26%+26.15%+45.30% 40.02TCr
Weighted average by Cap. +0.26%+3.09%+35.15%+61.76%

Financials

2026 *2027 *
Net sales 6.31TCr 5.5TCr 5.2TCr 4.72TCr 8.84TCr 6,05700Cr 8.88TCr 62TCr 24TCr 3,07900Cr 24TCr 23TCr 9,90800Cr 6.7TCr 5.84TCr 5.51TCr 5.01TCr 9.38TCr 6,42700Cr 9.42TCr 66TCr 25TCr 3,26700Cr 25TCr 25TCr 10,51300Cr
Net income 1.21TCr 1.05TCr 993.91Cr 902.55Cr 1.69TCr 1,15800Cr 1.7TCr 12TCr 4.59TCr 59TCr 4.53TCr 4.43TCr 1,89500Cr 1.38TCr 1.2TCr 1.14TCr 1.03TCr 1.93TCr 1,32500Cr 1.94TCr 14TCr 5.25TCr 67TCr 5.19TCr 5.07TCr 2,16700Cr
Net Debt 1.97TCr 1.72TCr 1.62TCr 1.47TCr 2.76TCr 1,89000Cr 2.77TCr 19TCr 7.5TCr 96TCr 7.4TCr 7.23TCr 3,09100Cr 1.19TCr 1.04TCr 982.35Cr 892.05Cr 1.67TCr 1,14500Cr 1.68TCr 12TCr 4.54TCr 58TCr 4.48TCr 4.38TCr 1,87300Cr
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
25
Last Close Price
167.18USD
Average target price
211.39USD
Spread / Average Target
+26.44%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!